TKIs beyond immunotherapy predict improved survival in advanced HCC.
Publication/Presentation Date
6-30-2022
Abstract
PURPOSE: For patients with advanced HCC, predictors of immunotherapy response are scarce, and the benefits of tyrosine kinase inhibitor (TKI) treatment after immunotherapy are unclear. We explored whether clinical features, such as target lesion response, immune-mediated toxicity, or subsequent TKI therapy predict immunotherapy response.
METHODS: We retrospectively studied 77 patients with advanced HCC receiving immunotherapy. Patient characteristics and outcomes were assessed using various statistical methods, including the log-rank test and Kaplan-Meier methods. Cox proportional hazard modeling was used for multivariable survival analysis.
RESULTS: For all patients, median overall survival (mOS) was 13 months (95% CI 8-19), and median progression-free survival (mPFS) was 6 months (95% CI 4-10). Patients with partial response (PR) and stable disease (SD) compared to progressive disease (PD) had prolonged mPFS (27 vs. 5 vs. 1 month(s), p < 0.0001) and mOS (not met vs. 11 vs. 3 months, p < 0.0001). Patients with vs. without immune-mediated toxicities trended towards longer mPFS (9 vs. 4 months p = 0.133) and mOS (17 vs. 9 months; p = 0.095). Patients who did vs. did not receive a tyrosine kinase inhibitor (TKI) after immunotherapy had a significantly improved mOS (19 vs. 5 months, p = 0.0024)). Based on multivariate modeling, the hazard ratio (HR) of overall survival (OS) of patients receiving TKI vs. no TKI was 0.412 (p = 0.0043).
CONCLUSION: We show that disease control predicts prolonged mOS and mPFS. Furthermore, TKI therapy administered after immunotherapy predicts prolonged mOS in patients with advanced HCC.
ISSN
1432-1335
Published In/Presented At
Armstrong, S., Roy, T., Singh, B., Kulasekaran, M., Shaukat, F., Geng, X., Wang, H., Prins, P., Jha, R. C., Hartley, M. L., & He, A. R. (2022). TKIs beyond immunotherapy predict improved survival in advanced HCC. Journal of cancer research and clinical oncology, 10.1007/s00432-022-04115-w. Advance online publication. https://doi.org/10.1007/s00432-022-04115-w
Disciplines
Medicine and Health Sciences
PubMedID
35773429
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article